Sensei (SNSE) Q2 Loss Narrows 31%
Sensei Biotherapeutics (NASDAQ:SNSE) is a clinical-stage immunotherapy company developing innovative antibody treatments for cancer. On August 5, 2025, it reported financial results for the second quarter of 2025. The key news was that loss per share was $(3.91) in Q2 2025 (GAAP), which was significantly better than the $(5.60) loss analysts had expected. The company reported a net loss of $4.9 million in Q2 2025 (GAAP) compared to a $7.1 million GAAP net loss for Q2 2024. No revenue was reported, consistent with its early-stage biotech status. The quarter reflected solid cost control and continued focus on advancing its lead asset. Overall, results exceeded earnings expectations and kept the company's operations on a stable funding path into next year.
Source: Analyst estimates for the quarter provided by FactSet.
Sensei Biotherapeutics is developing targeted antibody drugs, with its main product candidate solnerstotug at the center of its research. Solnerstotug is a monoclonal antibody, meaning it is a protein designed to attach to a specific molecule in the body—in this case, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation), which acts as an immune checkpoint in cancer.
Source Fool.com
